Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma

Jie Xu, Li Fan Zeng, Weihua Shen, John Turchi, Zhong-Yin Zhang

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Targeted therapy with inhibitors of epidermal growth factor receptor (EGFR) has produced a noticeable benefit to non-small cell lung cancer (NSCLC) patients whose tumors carry activating mutations (e.g. L858R) in EGFR. Unfortunately, these patients develop drug resistance after treatment, due to acquired secondary gatekeeper mutations in EGFR (e.g. T790M). Given the critical role of SHP2 in growth factor receptor signaling, we sought to determine whether targeting SHP2 could have therapeutic value for EGFR inhibitor resistant NSCLC. We show that SHP2 is required for EGF-stimulated ERK1/2 phosphorylation and proliferation in EGFR inhibitor resistant NSCLC cell line H1975, which harbors the EGFR T790M/L858R double-mutant. We demonstrate that treatment of H1975 cells with II-B08, a specific SHP2 inhibitor, phenocopies the observed growth inhibition and reduced ERK1/2 activation seen in cells treated with SHP2 siRNA. Importantly, we also find that II-B08 exhibits marked anti-tumor activity in H1975 xenograft mice. Finally, we observe that combined inhibition of SHP2 and PI3K impairs both the ERK1/2 and PI3K/AKT signaling axes and produces significantly greater effects on repressing H1975 cell growth than inhibition of either protein individually. Collectively, these results suggest that targeting SHP2 may represent an effective strategy for treatment of EGFR inhibitor resistant NSCLCs.

Original languageEnglish
Pages (from-to)586-590
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume439
Issue number4
DOIs
StatePublished - Oct 4 2013

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Cells
Phosphatidylinositol 3-Kinases
Tumors
Therapeutics
Mutation
Phosphorylation
Growth Factor Receptors
Cell growth
Growth
Ports and harbors
Drug Resistance
Epidermal Growth Factor
Heterografts
Small Interfering RNA
Neoplasms
Chemical activation
Cell Line
Pharmaceutical Preparations

Keywords

  • Drug resistance
  • EGFR
  • Lung cancer
  • Phosphatase inhibitor
  • SHP2

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma. / Xu, Jie; Zeng, Li Fan; Shen, Weihua; Turchi, John; Zhang, Zhong-Yin.

In: Biochemical and Biophysical Research Communications, Vol. 439, No. 4, 04.10.2013, p. 586-590.

Research output: Contribution to journalArticle

@article{6e2de1a8d3dc4041aa597a6721588c2b,
title = "Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma",
abstract = "Targeted therapy with inhibitors of epidermal growth factor receptor (EGFR) has produced a noticeable benefit to non-small cell lung cancer (NSCLC) patients whose tumors carry activating mutations (e.g. L858R) in EGFR. Unfortunately, these patients develop drug resistance after treatment, due to acquired secondary gatekeeper mutations in EGFR (e.g. T790M). Given the critical role of SHP2 in growth factor receptor signaling, we sought to determine whether targeting SHP2 could have therapeutic value for EGFR inhibitor resistant NSCLC. We show that SHP2 is required for EGF-stimulated ERK1/2 phosphorylation and proliferation in EGFR inhibitor resistant NSCLC cell line H1975, which harbors the EGFR T790M/L858R double-mutant. We demonstrate that treatment of H1975 cells with II-B08, a specific SHP2 inhibitor, phenocopies the observed growth inhibition and reduced ERK1/2 activation seen in cells treated with SHP2 siRNA. Importantly, we also find that II-B08 exhibits marked anti-tumor activity in H1975 xenograft mice. Finally, we observe that combined inhibition of SHP2 and PI3K impairs both the ERK1/2 and PI3K/AKT signaling axes and produces significantly greater effects on repressing H1975 cell growth than inhibition of either protein individually. Collectively, these results suggest that targeting SHP2 may represent an effective strategy for treatment of EGFR inhibitor resistant NSCLCs.",
keywords = "Drug resistance, EGFR, Lung cancer, Phosphatase inhibitor, SHP2",
author = "Jie Xu and Zeng, {Li Fan} and Weihua Shen and John Turchi and Zhong-Yin Zhang",
year = "2013",
month = "10",
day = "4",
doi = "10.1016/j.bbrc.2013.09.028",
language = "English",
volume = "439",
pages = "586--590",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma

AU - Xu, Jie

AU - Zeng, Li Fan

AU - Shen, Weihua

AU - Turchi, John

AU - Zhang, Zhong-Yin

PY - 2013/10/4

Y1 - 2013/10/4

N2 - Targeted therapy with inhibitors of epidermal growth factor receptor (EGFR) has produced a noticeable benefit to non-small cell lung cancer (NSCLC) patients whose tumors carry activating mutations (e.g. L858R) in EGFR. Unfortunately, these patients develop drug resistance after treatment, due to acquired secondary gatekeeper mutations in EGFR (e.g. T790M). Given the critical role of SHP2 in growth factor receptor signaling, we sought to determine whether targeting SHP2 could have therapeutic value for EGFR inhibitor resistant NSCLC. We show that SHP2 is required for EGF-stimulated ERK1/2 phosphorylation and proliferation in EGFR inhibitor resistant NSCLC cell line H1975, which harbors the EGFR T790M/L858R double-mutant. We demonstrate that treatment of H1975 cells with II-B08, a specific SHP2 inhibitor, phenocopies the observed growth inhibition and reduced ERK1/2 activation seen in cells treated with SHP2 siRNA. Importantly, we also find that II-B08 exhibits marked anti-tumor activity in H1975 xenograft mice. Finally, we observe that combined inhibition of SHP2 and PI3K impairs both the ERK1/2 and PI3K/AKT signaling axes and produces significantly greater effects on repressing H1975 cell growth than inhibition of either protein individually. Collectively, these results suggest that targeting SHP2 may represent an effective strategy for treatment of EGFR inhibitor resistant NSCLCs.

AB - Targeted therapy with inhibitors of epidermal growth factor receptor (EGFR) has produced a noticeable benefit to non-small cell lung cancer (NSCLC) patients whose tumors carry activating mutations (e.g. L858R) in EGFR. Unfortunately, these patients develop drug resistance after treatment, due to acquired secondary gatekeeper mutations in EGFR (e.g. T790M). Given the critical role of SHP2 in growth factor receptor signaling, we sought to determine whether targeting SHP2 could have therapeutic value for EGFR inhibitor resistant NSCLC. We show that SHP2 is required for EGF-stimulated ERK1/2 phosphorylation and proliferation in EGFR inhibitor resistant NSCLC cell line H1975, which harbors the EGFR T790M/L858R double-mutant. We demonstrate that treatment of H1975 cells with II-B08, a specific SHP2 inhibitor, phenocopies the observed growth inhibition and reduced ERK1/2 activation seen in cells treated with SHP2 siRNA. Importantly, we also find that II-B08 exhibits marked anti-tumor activity in H1975 xenograft mice. Finally, we observe that combined inhibition of SHP2 and PI3K impairs both the ERK1/2 and PI3K/AKT signaling axes and produces significantly greater effects on repressing H1975 cell growth than inhibition of either protein individually. Collectively, these results suggest that targeting SHP2 may represent an effective strategy for treatment of EGFR inhibitor resistant NSCLCs.

KW - Drug resistance

KW - EGFR

KW - Lung cancer

KW - Phosphatase inhibitor

KW - SHP2

UR - http://www.scopus.com/inward/record.url?scp=84884703820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884703820&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2013.09.028

DO - 10.1016/j.bbrc.2013.09.028

M3 - Article

C2 - 24041688

AN - SCOPUS:84884703820

VL - 439

SP - 586

EP - 590

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -